

ABSTRACTVACCINE

5 Effective stimulation of immune responses is achieved through the use of a
group A streptococcal antigen combined with proteosome adjuvant. The
compositions are provided in particular for intranasal administration. The vaccine
compositions are provided for use in inducing an immune response in an individual
for the treatment or prophylaxis of group A streptococcal infection in an individual,
10 preferably via prevention or reduction of colonisation of the throat following
intranasal administration.